Proposed section structure
This topic is best organized around the clinical burden of kidney dysfunction in cirrhosis, the design and global scope of the registry, the principal epidemiologic and prognostic findings, and the implications for inpatient management and prevention. The article therefore follows this structure: Highlights; Clinical background; Study design and methods; Key results; Interpretation and expert commentary; Practice implications; Limitations; Conclusion; Funding and trial registration; References.
Highlights
Chronic kidney disease (CKD) was present in 18.17% of 7040 non-electively admitted patients with cirrhosis enrolled across 127 sites worldwide, indicating that chronic renal dysfunction is a major comorbidity in contemporary cirrhosis care.
CKD was most prevalent in high-income countries, paralleling a higher burden of metabolic syndrome and suggesting that the epidemiology of kidney disease in cirrhosis is increasingly shaped by cardiometabolic risk.
Patients with both cirrhosis and CKD had more advanced portal hypertensive complications, especially ascites, and were far more likely to develop in-hospital acute kidney injury (AKI) than patients without CKD.
CKD identified a high-risk phenotype with significantly higher in-hospital and 30-day postdischarge mortality, underscoring the need for early recognition, prevention of AKI, and closer transitional care after discharge.
Clinical background
Kidney dysfunction is one of the most important determinants of prognosis in cirrhosis. In advanced liver disease, renal impairment may arise through several overlapping pathways: reduced effective arterial blood volume from splanchnic vasodilation, portal hypertension, recurrent infections, systemic inflammation, exposure to nephrotoxins, diabetes, hypertension, and intrinsic renal diseases such as diabetic nephropathy or glomerulopathies associated with chronic viral liver disease. Much of the literature in cirrhosis has historically focused on AKI and hepatorenal syndrome, because these syndromes often precipitate dramatic clinical deterioration. However, CKD is increasingly relevant as the patient population with cirrhosis ages and accumulates metabolic comorbidity.
CKD in cirrhosis is clinically challenging. Serum creatinine can underestimate the severity of renal dysfunction in patients with low muscle mass, and fluctuating volume status complicates interpretation of estimated glomerular filtration rate (eGFR). Even so, persistent reduction in GFR has important consequences. It limits the use of diuretics and other therapies, increases the risk of AKI during infections or large-volume fluid shifts, complicates transplant evaluation, and contributes to higher mortality. Current guidance from major liver societies emphasizes that kidney dysfunction in cirrhosis should be classified carefully because prognosis and management differ substantially between functional renal failure, intrinsic kidney disease, and chronic structural nephropathy.
The study by Wong and colleagues is timely because it addresses a major evidence gap: the global prevalence of CKD among hospitalized patients with cirrhosis and its effect on short-term outcomes in a large, prospective, multinational cohort.
Study design and methods
This investigation used data from the Chronic Liver Disease Evolution and Registry for Events and Decompensation consortium, a prospective international registry. The consortium enrolled non-electively admitted patients with cirrhosis from 127 sites globally, with each site contributing up to 100 patients. The study therefore reflects real-world inpatient cirrhosis practice across multiple health systems and World Bank income strata.
The primary analytic comparison was between patients with CKD (CKD+) and those without CKD (CKD-). CKD was defined using the conventional threshold of GFR less than 60 mL/min/1.73 m2 for more than 3 months. Collected variables included demographics, comorbid conditions, cirrhosis history, details of the hospital course, and outcomes. The investigators also compared patterns across World Bank income categories, allowing a broad view of how socioeconomic context may shape the burden of renal disease in cirrhosis.
The main outcomes highlighted in the abstract were the prevalence of CKD, associations with cirrhosis complications, development of in-hospital AKI, and mortality during hospitalization and within 30 days after discharge. Although the abstract does not provide adjusted effect estimates, confidence intervals, or detailed multivariable modeling, the scale and prospective nature of the cohort make the descriptive findings highly informative.
Key results
Global prevalence of CKD in hospitalized cirrhosis
Among 7040 enrolled inpatients with cirrhosis, the global prevalence of CKD was 18.17%. This is a clinically meaningful figure: roughly 1 in 5 hospitalized patients with cirrhosis carried pre-existing chronic renal dysfunction. For hepatologists and hospitalists, this means CKD is not a niche complication but part of the baseline risk architecture of modern decompensated cirrhosis care.
The prevalence was highest in high-income countries. Importantly, this geographic pattern paralleled a higher prevalence of metabolic syndrome. That observation is plausible biologically and epidemiologically. In many higher-income settings, cirrhosis increasingly arises in the context of metabolic dysfunction-associated steatotic liver disease, diabetes, obesity, and hypertension, all of which also accelerate CKD. The findings support the view that cirrhosis care can no longer be compartmentalized from cardiovascular and renal risk management.
Baseline renal function and disease complexity
As expected, kidney function at enrollment was markedly worse in CKD+ patients. The median enrollment GFR was 32 mL/min/1.73 m2 (IQR 21 to 44) in the CKD+ group versus 88 mL/min/1.73 m2 (IQR 63 to 117) in the CKD- group, with p<0.0001. The magnitude of this separation suggests that the CKD classification captured a population with substantial renal vulnerability rather than minor reductions in filtration.
CKD+ patients also had a more complicated history of cirrhosis decompensation. Ascites was present in 76.5% of CKD+ patients compared with 61.1% of CKD- patients, again with p<0.0001. This is clinically important because ascites both reflects and aggravates circulatory dysfunction in cirrhosis. Patients with recurrent or refractory ascites are exposed to repeated diuretic titration, paracentesis, albumin administration, infection risk, and intravascular volume shifts, all of which can interact adversely with chronic renal dysfunction.
The abstract does not enumerate all prior complications, but the phrase “more complex history of cirrhosis complications” suggests that CKD marks a more advanced and fragile phenotype. In practice, these patients often have lower physiologic reserve, more medication-related vulnerability, and less capacity to tolerate intercurrent illness.
Acute kidney injury as the dominant in-hospital complication
The most common in-hospital complication was AKI, occurring in 59.4% of CKD+ patients compared with 27% of CKD- patients (p<0.0001). This is perhaps the study’s most clinically actionable finding. CKD did not simply coexist with cirrhosis; it sharply amplified the risk of acute renal deterioration during hospitalization.
That pattern is consistent with what clinicians see at the bedside. CKD lowers renal reserve, so relatively modest insults such as infection, gastrointestinal bleeding, overdiuresis, contrast exposure, hypotension, or large-volume fluid shifts may precipitate AKI. In cirrhosis, AKI is particularly dangerous because it can herald progression to hepatorenal syndrome, worsened encephalopathy, longer hospitalization, intensive care use, and death. The nearly 60% AKI rate in the CKD+ group suggests that many of these patients enter the hospital already near the threshold of decompensation.
From a systems perspective, this finding argues for early kidney-protective protocols on admission for cirrhotic patients with known CKD. These may include strict review of nephrotoxins, close daily assessment of volume status, prompt treatment of infection, careful diuretic adjustment, and early albumin-based strategies where indicated by guideline-supported indications.
Mortality impact
CKD was associated with higher in-hospital mortality and higher 30-day postdischarge mortality, both with p<0.0001. Even without absolute risk values in the abstract, the message is clear: CKD identifies hospitalized patients with cirrhosis at elevated short-term risk both during the index admission and shortly after transition back to the community.
This postdischarge signal is especially relevant. Cirrhosis readmissions and early postdischarge deaths are common, often driven by recurrent ascites, encephalopathy, infection, and renal events. If CKD continues to influence outcomes after discharge, then inpatient stabilization alone is not enough. These patients likely need structured follow-up, rapid access to laboratory monitoring, medication reconciliation, nutritional assessment, and early specialist review.
Interpretation and expert commentary
This study extends the conversation about kidney dysfunction in cirrhosis beyond AKI and hepatorenal syndrome. It demonstrates that CKD is common globally among hospitalized cirrhosis patients and that it materially worsens prognosis. Conceptually, it supports a model in which chronic renal dysfunction is both a marker and a mediator of poor outcome.
Why might CKD be so detrimental in cirrhosis? Several mechanisms are likely involved. First, CKD often co-travels with diabetes, hypertension, vascular disease, and systemic inflammation, all of which increase physiologic frailty. Second, impaired renal reserve magnifies susceptibility to AKI, and AKI itself is a major driver of mortality in cirrhosis. Third, CKD restricts therapeutic flexibility: clinicians may be less able to intensify diuretics, use certain antibiotics, or tolerate hemodynamic perturbations. Fourth, CKD may identify patients with long-standing metabolic disease, a phenotype increasingly common in high-income countries and often accompanied by sarcopenia, cardiovascular disease, and poorer transplant candidacy.
The geographic gradient is also noteworthy. The highest CKD prevalence in high-income countries likely reflects a combination of older patient age, longer survival with chronic liver disease, better documentation of CKD, and a larger burden of metabolic syndrome. This does not necessarily mean lower-income countries are protected; rather, case mix differs, and under-recognition of CKD may also play a role where longitudinal renal data are less available.
Current clinical guidelines already stress the importance of distinguishing AKI from CKD and of evaluating structural kidney disease in cirrhosis. The American Association for the Study of Liver Diseases and the International Club of Ascites have emphasized a structured approach that includes serum creatinine trends, urinalysis, albuminuria, renal imaging, medication review, and attention to precipitating factors. The present study adds real-world international evidence that this classification effort has direct prognostic value.
Practice implications
1. Screen and phenotype kidney disease early
Hospitalized patients with cirrhosis should be assessed not only for current AKI but also for underlying CKD. Historical creatinine values, prior eGFR trends, albuminuria or proteinuria, diabetic status, hypertension history, and renal ultrasound findings can help identify chronic structural kidney disease. Because sarcopenia may make creatinine deceptively low, clinicians should interpret eGFR cautiously and consider the full clinical context.
2. Treat ascites meticulously
The strong association between CKD and ascites supports careful ascites management as a potential modifiable target. This includes individualized sodium restriction, judicious diuretic use, timely large-volume paracentesis with albumin replacement when indicated, surveillance for spontaneous bacterial peritonitis, and avoidance of excessive intravascular depletion. In patients with recurrent renal dysfunction, repeated re-evaluation of the ascites strategy is warranted.
3. Prevent AKI aggressively during admission
The near doubling of AKI risk in CKD+ patients should trigger heightened prevention efforts. Common steps include avoiding nonsteroidal anti-inflammatory drugs and other nephrotoxins, minimizing unnecessary contrast exposure, rapidly treating infection and gastrointestinal bleeding, reassessing renin-angiotensin system blockers where appropriate, monitoring urine output and daily creatinine, and maintaining hemodynamic stability.
4. Address metabolic risk, especially in high-income settings
The linkage between CKD prevalence and metabolic syndrome is an important translational message. Weight management, diabetes optimization, blood pressure control, and cardiovascular risk reduction are relevant not only to kidney outcomes but increasingly to liver disease trajectories as well. For health systems in high-income countries, the inpatient encounter may be an opportunity to integrate hepatology, nephrology, and metabolic care.
5. Strengthen discharge planning
Because mortality remained elevated at 30 days after discharge, CKD+ patients should be considered for enhanced transitional care. That may include early follow-up appointments, repeat renal and liver laboratory testing, review of diuretic doses, patient education on infection warning signs, and low thresholds for reassessment if weight, urine output, abdominal distension, or mentation changes.
Strengths and limitations
The study has several important strengths. It is prospective, large, and multinational, with 7040 patients enrolled across 127 sites. It examines real-world, non-elective hospital admissions, the setting in which morbidity and mortality from cirrhosis are most concentrated. It also adds valuable global context by comparing World Bank income strata.
There are also limitations that matter for interpretation. First, the abstract does not provide adjusted hazard ratios or odds ratios, so the degree to which CKD independently predicts mortality beyond overall liver disease severity cannot be fully assessed from the available information. Second, CKD classification in cirrhosis can be difficult, especially where historical laboratory data are incomplete or creatinine-based GFR estimation is imprecise. Third, because the cohort is restricted to hospitalized patients, the findings should not be extrapolated directly to all outpatients with compensated cirrhosis. Fourth, site-level variation in practice patterns, diagnostic coding, and access to nephrology care may influence observed prevalence and outcomes. Finally, the abstract does not clarify the etiology of CKD, which would be clinically useful because diabetic kidney disease, hypertensive nephrosclerosis, and glomerular disease may carry different trajectories.
Conclusion
This global prospective study shows that CKD is present in nearly one-fifth of non-electively admitted patients with cirrhosis and marks a distinctly high-risk population. CKD clusters with more advanced decompensation, especially ascites, sharply increases the likelihood of in-hospital AKI, and is associated with higher mortality during hospitalization and within 30 days of discharge. The burden appears greatest in high-income countries, likely reflecting the growing contribution of metabolic syndrome to both liver and kidney disease.
For clinicians, the practical message is straightforward: in cirrhosis, chronic kidney dysfunction deserves the same diagnostic urgency and longitudinal attention that AKI already receives. Careful ascites management, rigorous AKI prevention, integrated metabolic risk reduction, and stronger postdischarge surveillance are reasonable targets for improving outcomes. Future reports from this cohort should clarify adjusted risk estimates, CKD phenotypes, and whether specific management strategies can modify this excess mortality.
Funding and ClinicalTrials.gov
The abstract provided does not specify funding details or a ClinicalTrials.gov registration number. Readers should consult the full Gut publication for complete disclosures, funding sources, and any registry identifiers.
References
1. Wong F, Adebayo D, George J, Idilman R, Hayes PC, Alvares-da-Silva MR, Torre A, Mekonnen HD, Seto WK, Sarin SK, Cao Z, Rajoriya N, Nagral A, Fisseha H, Kulkarni AV, Zhu C, Debzi N, Farias AQ, Su M, Goel A, Marciano S, Livingstone R, Dhiman RK, Gao Y, Malé-Velázquez R, Demitars CO, Bera C, Jiang YF, Velarde-Ruiz Velasco JA, Tan HK, Zhao C, Huezo MSG, Asrani SK, Wang L, Lu M, Michalczuk MT, Barutcu S, Cordova-Gallardo J, Gofton C, Gounder M, Shaw J, Albhaisi S, Zheng X, Aravinthan A, Rajaram RB, Jothimani D, Thanapirom K, Benitez C, Dincer D, Saraya A, Xu B, Lin M, Wu X, Liu C, Reddy R, Bush B, Thacker LR, Topazian M, Xie Q, Silvey S, Kamath PS, Choudhury A, Bajaj JS, CLEARED Investigators. Chronic kidney disease in cirrhosis: a study of inpatients from a global perspective. Gut. 2026-06-05. PMID: 42248676.
2. Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR. News in pathophysiology, definition and classification of hepatorenal syndrome: a step beyond the International Club of Ascites criteria. J Hepatol. 2019;71(4):811-822.
3. Biggins SW, Angeli P, Garcia-Tsao G, Ginès P, Ling SC, Nadim MK, Wong F, Kim WR. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021;74(2):1014-1048.
4. Francoz C, Nadim MK, Durand F. Kidney biomarkers in cirrhosis. J Hepatol. 2016;65(4):809-824.
5. Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int. 2018;12(Suppl 1):122-134.